{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:30:28Z","timestamp":1790094628501,"version":"4.0.1"},"reference-count":96,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Janus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of information from receptors located in the cell membrane to the cell interior, specifically to the cell nucleus, thus disrupting the JAK-STAT pathway. This pathway plays a role in key cellular processes such as the immune response and cell growth. This feature is used in the treatment of patients with rheumatological, gastroenterological and hematological diseases. Recently, it has been discovered that JAK-STAT pathway inhibitors also show therapeutic potential against dermatological diseases such as atopic dermatitis, psoriasis, alopecia areata and acquired vitiligo. Studies are underway to use them in the treatment of several other dermatoses. Janus kinase inhibitors represent a promising class of drugs for the treatment of skin diseases refractory to conventional therapy. The purpose of this review is to summarize the latest knowledge on the use of JAKi in dermatological treatment.<\/jats:p>","DOI":"10.3390\/molecules28248064","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T12:00:37Z","timestamp":1702468837000},"page":"8064","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1759-2140","authenticated-orcid":false,"given":"Izabella","family":"Rygu\u0142a","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Pikiewicz","sequence":"additional","affiliation":[{"name":"Department of Medical and Health Sciences, Collegium Medicum\u2014Faculty of Medicine, WSB University, 41-300 D\u0105browa G\u00f3rnicza, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7481-2621","authenticated-orcid":false,"given":"Konrad","family":"Kamini\u00f3w","sequence":"additional","affiliation":[{"name":"Department of Medical and Health Sciences, Collegium Medicum\u2014Faculty of Medicine, WSB University, 41-300 D\u0105browa G\u00f3rnicza, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging Topical and Systemic JAK Inhibitors in Dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/jdv.14673","article-title":"Immune response patterns in non-communicable inflammatory skin diseases","volume":"32","author":"Eyerich","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00281-015-0545-x","article-title":"Cutaneous immunology: Basics and new concepts","volume":"38","author":"Yazdi","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"ref_4","first-page":"4","article-title":"Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications","volume":"27","author":"Shalabi","year":"2022","journal-title":"Skin Ther. Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.25259\/IJDVL_1152_2022","article-title":"JAK-STAT inhibitors in Immune mediated diseases: An Overview","volume":"89","author":"Shah","year":"2023","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/BOR.0000000000000810","article-title":"Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: Rationale and evidence for JAK inhibition","volume":"33","author":"Raychaudhuri","year":"2021","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/art.41906","article-title":"A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?","volume":"73","author":"Liu","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: Impact on human disease and therapeutic intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fonc.2018.00287","article-title":"\u201cDo We Know Jack\u201d About JAK? A Closer Look at JAK\/STAT Signaling Pathway","volume":"8","author":"Bousoik","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Smith, P., Yao, W., Shepard, S., Covington, M., Lee, J., Lofland, J., Naim, A., Sheth, T., Parikh, B., and Yeleswaram, S. (2021). Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071044"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tsiogka, A., Kyriazopoulou, M., Kontochristopoulos, G., Nicolaidou, E., Stratigos, A., Rigopoulos, D., and Gregoriou, S. (2022). The JAK\/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154431"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Caiazzo, G., Caiazzo, A., Napolitano, M., Megna, M., Potestio, L., Fornaro, L., Parisi, M., Luciano, M.A., Ruggiero, A., and Testa, A. (2023). The Use of JAK\/STAT Inhibitors in Chronic Inflammatory Disorders. Clin. Med., 12.","DOI":"10.3390\/jcm12082865"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: Autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rusi\u00f1ol, L., and Puig, L. (2023). Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043391"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Liau, N.P.D., Laktyushin, A., Morris, R., Sandow, J.J., Nicola, N.A., Kershaw, N.J., and Babon, J.J. (2019). Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1. Cancers, 11.","DOI":"10.3390\/cancers11111701"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tem.2017.11.001","article-title":"JAK\/STAT\u2014Emerging Players in Metabolism","volume":"29","author":"Dodington","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12964-023-01240-y","article-title":"Double-edged sword of JAK\/STAT signaling pathway in viral infections: Novel insights into virotherapy","volume":"21","author":"Mahjoor","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hu, Q., Bian, Q., Rong, D., Wang, L., Song, J., Huang, H.S., Zeng, J., Mei, J., and Wang, P.Y. (2023). JAK\/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1110765"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Liu, J., Wang, F., and Luo, F. (2023). The Role of JAK\/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms. Biomolecules, 13.","DOI":"10.3390\/biom13010119"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"955035","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus Kinase Family in Autoimmune Skin Diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_24","unstructured":"American Academy of Dermatology Association (2023, October 18). Jak Inhibitors: What Your Dermatologist Wants You to Know. Available online: https:\/\/www.aad.org\/public\/diseases\/a-z\/jak-inhibitors."},{"key":"ref_25","first-page":"5","article-title":"Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology","volume":"23","author":"Cinats","year":"2018","journal-title":"Skin Ther. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and Safety of Baricitinib Combined with Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ad.2023.06.012","article-title":"Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders","volume":"114","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12016-021-08880-3","article-title":"Update on the Pathogenesis and Therapy of Atopic Dermatitis","volume":"61","author":"Li","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/all.13231","article-title":"Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide","volume":"73","author":"Thyssen","year":"2018","journal-title":"Allergy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/ds.ds_20_20","article-title":"Association of atopic dermatitis with inflammatory bowel disease: A systematic review and meta-analysis","volume":"38","author":"Wang","year":"2020","journal-title":"Dermatol. Sin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.0105-2896.2004.00209.x","article-title":"Signaling pathways in Th2 development","volume":"202","author":"Mowen","year":"2004","journal-title":"Immunol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100195","DOI":"10.1016\/j.xjidi.2023.100195","article-title":"Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence","volume":"3","author":"Kamata","year":"2023","journal-title":"JID Innov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin. Immunol."},{"key":"ref_35","first-page":"e24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAKSTAT"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/jid.2014.43","article-title":"Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6)","volume":"134","author":"Brauweiler","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clim.2007.11.006","article-title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6","volume":"126","author":"Kim","year":"2008","journal-title":"Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jaci.2015.06.047","article-title":"Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum","volume":"136","author":"Gao","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies","volume":"88","author":"Papp","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): Results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Teixeira","year":"2021","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaad.2023.05.033","article-title":"Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15,000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40257-023-00785-5","article-title":"Efficacy and Safety of Abrocitinib in Patients with Severe and\/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial","volume":"24","author":"Simpson","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e16704","DOI":"10.1016\/j.heliyon.2023.e16704","article-title":"Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis","volume":"9","author":"Gao","year":"2023","journal-title":"Heliyon"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2190430","DOI":"10.1080\/09546634.2023.2190430","article-title":"Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial","volume":"34","author":"Thyssen","year":"2023","journal-title":"J. Dermatolog. Treat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.21015","article-title":"The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials","volume":"186","author":"Yosipovitch","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term Efficacy of Baricitinib in Adults with Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials","volume":"157","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s12325-023-02445-w","article-title":"Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications","volume":"40","author":"Taylor","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e2320351","DOI":"10.1001\/jamanetworkopen.2023.20351","article-title":"Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis","volume":"6","author":"Liu","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e13378","DOI":"10.1111\/srt.13378","article-title":"Trichoscopy pattern in alopecia areata: A systematic review and meta-analysis","volume":"29","author":"Alsenaid","year":"2023","journal-title":"Skin Res. Technol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2023-6-2","DOI":"10.7573\/dic.2023-6-2","article-title":"Efficacy and safety of baricitinib in patients with alopecia areata: Evidence to date","volume":"12","author":"Faria","year":"2023","journal-title":"Drugs Context"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.crimmu.2021.02.001","article-title":"Immunopathogenesis of alopecia areata","volume":"2","author":"Olayinka","year":"2021","journal-title":"Curr. Res. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/exd.14129","article-title":"Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata","volume":"29","author":"Ito","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/sj.jid.5701183","article-title":"Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack","volume":"128","author":"Ito","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_60","unstructured":"(2023, October 19). Available online: https:\/\/news.yale.edu\/2023\/06\/26\/fda-approves-second-yale-researched-treatment-alopecia-areata."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two Phase 3 Trials of Baricitinib for Alopecia Areata","volume":"386","author":"King","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: First Approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: A randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e13740","DOI":"10.1111\/dth.13740","article-title":"How can I take care of you? The dermatologist meets patients\u2019 needs during the COVID-19 pandemic","volume":"33","author":"Radi","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"636","DOI":"10.5114\/ada.2021.108896","article-title":"Translation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality of life instrument (VitiQoL) into Polish","volume":"38","author":"Iwanowski","year":"2021","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Diotallevi, F., Gioacchini, H., De Simoni, E., Marani, A., Candelora, M., Paolinelli, M., Molinelli, E., Offidani, A., and Simonetti, O. (2023). Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054910"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.5021\/ad.23.065","article-title":"Understanding of Pathomechanisms and Clinical Practice for Vitiligo","volume":"35","author":"Tanemura","year":"2023","journal-title":"Ann. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2012-07-446146","article-title":"Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack","volume":"121","author":"Lopez","year":"2013","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/pcmr.12667","article-title":"CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: A multicenter cross-sectional study","volume":"31","author":"Abdallah","year":"2018","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1203475419833609","article-title":"The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature","volume":"23","author":"Relke","year":"2019","journal-title":"J. Cutan Med. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2340\/00015555-2080","article-title":"Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8+ Cytotoxic T Lymphocytes in Vitiligo","volume":"95","author":"Yang","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"ref_74","unstructured":"(2023, October 25). Available online: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"adv00030","DOI":"10.2340\/00015555-3384","article-title":"Psoriasis and Genetics","volume":"100","author":"Dand","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_78","unstructured":"World Health Organization (2016). Global Report on Psoriasis, World Health Organization. Available online: http:\/\/www.who.int\/iris\/handle\/10665\/204417."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.07.007","article-title":"Psoriasis: A mixed autoimmune and autoinflammatory disease","volume":"49","author":"Liang","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.clindermatol.2007.08.013","article-title":"Resident skin cells in psoriasis: A special look at the pathogenetic functions of keratinocytes","volume":"25","author":"Albanesi","year":"2007","journal-title":"Clin. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2249.2007.03356.x","article-title":"The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease","volume":"148","author":"Afzali","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Boutet, M.A., Nerviani, A., Gallo Afflitto, G., and Pitzalis, C. (2018). Role of the IL-23\/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020530"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2741\/4054","article-title":"IL-6, IL-17 and STAT3: A holy trinity in auto-immunity?","volume":"17","author":"Camporeale","year":"2012","journal-title":"Front. Biosci. Landmark Ed."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_87","unstructured":"(2023, October 25). Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/annrheumdis-2022-eular.1016","article-title":"POS0239 risk of venous thromboembolic events in patients with rheumatoid arthritis aged \u2265 50 years with \u2265 1 cardiovascular risk factor: Results from a phase 3b\/4 randomised study of tofacitinib vs tumour necrosis factor inhibitors","volume":"81","author":"Fleischmann","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/annrheumdis-2022-eular.1182","article-title":"POS0237 major adverse cardiovascular events, malignancies and venous thromboembolism by baseline cardiovascular risk: A post hoc analysis of oral surveillance","volume":"81","author":"Buch","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2021.1570","article-title":"Incidence of Venous Thromboembolism in Patients with Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases","volume":"157","author":"Schneeweiss","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Pangan","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): Results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and Safety of Upadacitinib in Patients with Moderate to Severe Atopic Dermatitis: Analysis of Follow-Up Data from the Measure Up 1 and Measure Up 2 Randomized Clinical Trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/24\/8064\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:37:57Z","timestamp":1760132277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/24\/8064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":96,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["molecules28248064"],"URL":"https:\/\/doi.org\/10.3390\/molecules28248064","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]}}}